Lexaria Bioscience -CW25LEXXWPreferred / convertible
13F holders, Q3 2024 (September 30)3holders
0new positions
0sold out
$0.92avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding Lexaria Bioscience -CW25 (LEXXW) in their 13F filings, unchanged from Q2 2024. 0 opened new positions and 0 sold out. The largest holders were Heights Capital Management, Inc. ($38K), UBS Group AG ($26K) and Clear Street LLC ($184).
- Company
- Lexaria Bioscience -CW25
- CUSIP
- 52886N117
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 100 shares bought and 65,657 shares sold, net −65,557 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Heights Capital Management, Inc. | — | — | 41,251 | $38K |
| UBS Group AG | — | Reduce -70.1% | 28,065 | $26K |
| Clear Street LLC | — | Add +100.0% | 200 | $184 |
"% of holder's portfolio" is LEXXW's weight in each manager's 13F, not the share of Lexaria Bioscience -CW25 the manager owns.